• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

An Unusual Cause Of Recurrent Ischemic Stroke: Trousseau's Syndrome From Gastric Cancer (P4.231)
CONCLUSIONS: Trousseau’s Syndrome must be considered in those presenting with recurrent strokes with an otherwise negative embolic work up especially in the elderly and those with cancer risk factors. It must prompt the clinician to look for an associated malignancy.Disclosure: Dr. JADEJA has nothing to disclose. Dr. Johnson has nothing to disclose. Dr. Soetanto has nothing to disclose. Dr. Nalleballe has nothing to disclose. Dr. DeNiro has nothing to disclose. Dr. Qureshi has nothing to disclose. Dr. Graber has received personal compensation for activities with Stemedica Inc., Novocure Inc., and Biogen Idec.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Jadeja, N., Johnson, J., Soetanto, A., Nalleballe, K., DeNiro, L., Qureshi, I., Graber, J. Tags: Neuro-oncology: Paraneoplastic Disorders Source Type: research

New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news